Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report

References

• Liu DM, Song TQ. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. Biosci Trends. 2021;15(3):142–147. doi:10.5582/bst.2021.01083
   PubMed Web of Science ®Google Scholar
• Wang XY, Huang JM, Lu XM, et al. Changing risk factors for hepatocellular carcinoma in hyperendemic regions in the era of universal hepatitis B vaccination. Cancer Epidemiol. 2020;67:101775. doi:10.1016/j.canep.2020.101775
   PubMed Web of Science ®Google Scholar
• Yuan JM, Govindarajan S, Henderson BE, Yu MC. Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People’s Republic of China. Br J Cancer. 1996;74(3):491–493. doi:10.1038/bjc.1996.389
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223–238. doi:10.1016/j.cld.2015.01.001
   PubMed Web of Science ®Google Scholar
• Wong MCS, Huang JLW, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57–73. doi:10.1038/s41575-018-0055-0
   PubMed Web of Science ®Google Scholar
• Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon. 2012;12(10 HCC):e7635. doi:10.5812/hepatmon.7635
   PubMed Web of Science ®Google Scholar
• Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580–593. doi:10.1038/bjc.2014.579
   PubMed Web of Science ®Google Scholar
• Jinjuvadia R, Patel S, Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma systemic review and meta-analysis. J Clin Gastroenterol. 2014;48(2):172–177. doi:10.1097/MCG.0b013e3182a030c4
   PubMed Web of Science ®Google Scholar
• Han CY, Yu TD, Qin W, et al. Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus. J Gastrointest Oncol. 2020;11(6):1333–+. doi:10.21037/jgo-20-510
   PubMed Web of Science ®Google Scholar
• Zhu Q, Ma YR, Liang JB, et al. AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduct Tar. 2021;6:1.
   PubMed Web of Science ®Google Scholar
• Zhou R, Liu MZ, Liang XL, Su M, Li R. Clinical features of aflatoxin B1-exposed patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells. Environ Toxicol Phar. 2019;2019:71.
   Google Scholar
• Long XD, Ma Y, Zhou YF, Ma AM, Fu GH. Polymorphism in xeroderma pigmentosum complementation group C Codon 939 and aflatoxin B1-related hepatocellular carcinoma in the guangxi population. Hepatology. 2010;52(4):1301–1309.
   PubMed Web of Science ®Google Scholar
• Sugawara Y, Hibi T. Surgical treatment of hepatocellular carcinoma. Biosci Trends. 2021;15(3):138–141.
   PubMed Web of Science ®Google Scholar
• Liu JG, Zhang JJ, Wang YJ, Shu GM, Lou C, Du Z. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Medicine. 2022;101:51.
   Web of Science ®Google Scholar
• Mei JH, Yu HY, Qin LH, Jia ZZ. FOLFOX-HAIC for unresectable large hepatocellular carcinoma: the effectiveness has yet to be determined. J Clin Oncol. 2022;40(16):1841–+. doi:10.1200/JCO.21.02533
   PubMed Web of Science ®Google Scholar
• Yao W, Wei R, Jia J, et al. Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC. Ther Adv Med Oncol. 2023;2023:15.
   Google Scholar
• Sidaway P. FOLFOX-HAIC active in large HCC. Nat Rev Clin Oncol. 2022;19(1):5. doi:10.1038/s41571-021-00577-y
   PubMed Web of Science ®Google Scholar
• Comito T, Loi M, Franzese C, et al. Stereotactic radiotherapy after incomplete transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: a Phase III Trial (NCT02323360). Curr Oncol. 2022;29(11):8802–8813. doi:10.3390/curroncol29110692
   PubMed Web of Science ®Google Scholar
• Luo L, He Y, Zhu G, et al. Hepatectomy after conversion therapy for initially unresectable HCC: what is the difference? J Hepatocell Carcinoma. 2022;9:1353–1368. doi:10.2147/JHC.S388965
   PubMed Web of Science ®Google Scholar
• Kudo M. A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront Systemic therapy followed by curative conversion. Liver Cancer. 2021;10(6):539–544. doi:10.1159/000519749
   PubMed Web of Science ®Google Scholar
• Terzi E, Piccinnu M, Piscaglia F, et al. Survival of patients with hepatocellular Carcinoma (Hcc) within the bologna liver oncology group: comparison with international guidelines. Digest Liver Dis. 2015;47:E33–E. doi:10.1016/j.dld.2015.01.074
   Web of Science ®Google Scholar
• Ozdemir BH. Tumor microenvironment: necroptosis switches the subtype of liver cancer while necrosis promotes tumor recurrence and progression. Exp Clin Transplant. 2023;21(4):291–298. doi:10.6002/ect.2021.0457
   PubMed Web of Science ®Google Scholar
• Wu ZQ, Fan J, Qiu SJ, Zhou J, Tang ZY. The value of postoperative hepatic regional chemotherapy in prevention of recurrence after radical resection of primary liver cancer. World J Gastroentero. 2000;6(1):131–133. doi:10.3748/wjg.v6.i1.131
   PubMed Web of Science ®Google Scholar
• Qin S, Zhang X, Guo W, et al. Prognostic nomogram for advanced hepatocellular carcinoma treated with FOLFOX 4. Asian Pac J Cancer Prev. 2017;18(5):1225–1232. doi:10.22034/APJCP.2017.18.5.1225
   PubMedGoogle Scholar
• Li S, Mei J, Wang Q, et al. Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase III, randomized controlled clinical trial. Ann Surg Oncol. 2020;27(13):5183–5190. doi:10.1245/s10434-020-08601-8
   PubMed Web of Science ®Google Scholar
• Hsu SJ, Xu X, Chen MP, et al. Hepatic arterial infusion chemotherapy with modified FOLFOX as an alternative treatment option in advanced hepatocellular carcinoma patients with failed or unsuitability for transarterial chemoembolization. Acad Radiol. 2021;28(1):S157–S66. doi:10.1016/j.acra.2021.01.024
   PubMedGoogle Scholar
• Li S, Mei J, Wang Q, et al. Correction to: postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase III, randomized controlled clinical trial. Ann Surg Oncol. 2021;28(Suppl S3):874. doi:10.1245/s10434-021-09813-2
   PubMed Web of Science ®Google Scholar
• Huang J, Huang W, Zhan M, et al. Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1445–1458. doi:10.2147/JHC.S339379
   PubMed Web of Science ®Google Scholar
• Li S, Mei J, Wang Q, et al. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. Hepatobiliary Surg Nutr. 2021;10(5):631–645. doi:10.21037/hbsn.2020.03.14
   PubMed Web of Science ®Google Scholar
• Shinkawa H, Tanaka S, Takemura S, et al. Nomograms predicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma. Surgery. 2021;169(4):922–928. doi:10.1016/j.surg.2020.10.012
   PubMed Web of Science ®Google Scholar
• Mok KT, Wang BW, Lo GH, et al. Multimodality management of hepatocellular carcinoma larger than 10 cm. J Am Coll Surgeons. 2003;197(5):730–738. doi:10.1016/j.jamcollsurg.2003.07.013
   PubMed Web of Science ®Google Scholar
• He Q, Yang J, Jin Y. Development and validation of tace refractoriness-related diagnostic and prognostic scores and characterization of tumor microenvironment infiltration in hepatocellular carcinoma. Front Immunol. 2022;13:869993. doi:10.3389/fimmu.2022.869993
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013 global burden of disease cancer collaboration. JAMA Oncol. 2015;1(4):505–527. doi:10.1001/jamaoncol.2015.0735
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M, et al.; Global Burden of Disease Liver Cancer C. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Liver EAS, Liver EAS, Canc EORT. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(6):1430.
   Web of Science ®Google Scholar
• Verslype C, Rosmorduc O, Rougier P, Grp EGW. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:41–48. doi:10.1093/annonc/mds225
   Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi:10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Xue TC, Le F, Chen RX, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol. 2015;32(3). doi:10.1007/s12032-015-0504-3
   Web of Science ®Google Scholar
• Huang YH, Wu JC, Chen SC, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharm Ther. 2006;23(1):129–135. doi:10.1111/j.1365-2036.2006.02704.x
   PubMed Web of Science ®Google Scholar
• Gourd K, Lai C, Reeves C. ESMO Virtual Congress 2020. Lancet Oncol. 2020;21(11):1403–1404. doi:10.1016/S1470-2045(20)30585-4
   PubMed Web of Science ®Google Scholar
• Guo W, Gao J, Zhuang W, Wu Z, Li B, Chen S. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: a propensity score‐matching cohort study. JGH Open. 2019;4(3):477–483. doi:10.1002/jgh3.12285
   PubMed Web of Science ®Google Scholar